Headlines

MACK

Morning Watch List : Two Harbors Investment Corp. (NYSE:TWO), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Limoneira Company (NASDAQ:LMNR), ATRION Corp. (NASDAQ:ATRI), Ameriprise Financial, Inc. (NYSE:AMP),

Kevin Long03 mins

Two Harbors Investment Corp (NYSE:TWO) declared a quarterly dividend on Tuesday, September 16th, Analyst Ratings.Net reports. Stockholders of record on Tuesday, September 30th will be given a dividend of 0.26 per share on Tuesday, October 21st. This represents a $1.04 dividend on an annualized basis and a yield of 10.25%. The ex-dividend date of this…

Read More

Don’t Miss: Merrimack Pharmaceuticals (NASDAQ:MACK), Acorda Therapeutics (NASDAQ:ACOR), USA Compression Partners, LP (NYSE:USAC), Halliburton Company (NYSE:HAL), Google Inc. (NASDAQ:GOOG)

Kevin Long03 mins

On 4 AUG Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that the company will host its Second Quarter 2014 Investor Conference Call on Monday, August 11. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) belongs to Healthcare sector. Its weekly performance is 12.98%. On last trading day company shares ended up $6.53. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) distance from 50-day simple moving…

Read More

Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Ryan Holtz03 mins

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at…

Read More

Small Cap Insider Buying: Hercules Offshore (NASDAQ:HERO), Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros Corporation (NASDAQ:OMER), Insys (NASDAQ:INSY), New Mountain Finance (NYSE:NMFC)

Kristen Barton03 mins

Hercules Offshore Inc (NASDAQ:HERO) Director Thomas R. Bates, Jr. purchased 20,000 shares of the stock on the open market in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average price of $3.93 per share, for a total transaction of $78,600.00. Following the completion of the transaction, the director now…

Read More
Gilead Sciences GILD NASDAQ:GILD

Hot Biotech Watch List: InterMune Inc (NASDAQ:ITMN), Merrimack Pharmaceuticals (NASDAQ:MACK), China Biologic Products (NASDAQ:CBPO), VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA)

Kristen Barton03 mins

InterMune, Inc. (NASDAQ:ITMN) on 27 May 2014 announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). InterMune Inc…

Read More
Gilead Sciences GILD NASDAQ:GILD

Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Kevin Long02 mins

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares closed up nearly 11% on Tuesday after the company reported positive data from its OPuS-1 mid-stage study involving BCX4161 as a treatment for hereditary angioedema, or HAE. This is a rare immune disorder that can cause swelling of the face, breathing airways, and also causes abdominal cramping. According to the…

Read More
Home